Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer
Myrto Moutafi(University General Hospital Attikon), Ioannis Vathiotis(Yale Cancer Center)
Cited by 51
Related Papers
Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer
|Laboratory Investigation|2022|141
Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling
|Journal of Thoracic Oncology|2022|40
Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms
|EBioMedicine|2022|33
Spatial signatures for predicting immunotherapy outcomes using multi-omics in non-small cell lung cancer
|Nature Genetics|2025|33
Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
|Cancer Research Communications|2023|19